Neuropace Inc (NPCE)

Name: Neuropace Inc (NPCE) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Neuropace Inc (NPCE)

Stock Card

$14.41

$0.28 (1.98%)

As on 28-Aug-2026 16:22EDT

Market cap

$495 Mln

Revenue (TTM)

$99 Mln

P/E Ratio

P/B Ratio

40.8

Div. Yield

0 %

Neuropace Inc (NPCE) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 13.76 High: 14.55

52 Week Range

Low: 8.85 High: 19.60

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1 %
ROCE

-- %
Industry P/E

44.46
EV/EBITDA

-16.9
Debt to Equity

0
Book Value

$0.3
EPS

$-0.6
Face value

--
Shares outstanding

34,324,274

5 Years Aggregate

CFO

$-127.78 Mln

EBITDA

$-126.04 Mln

Net Profit

$-201.16 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Neuropace Inc (NPCE)	-6.7	-5.8	-15.5	62.3	33.9	-8.0	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Neuropace Inc (NPCE)	38.0	8.5	591.9	-85.2
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Neuropace Inc (NPCE)	14.4	494.6	98.8	-19.1	-13.6	-123.7	--	40.8
10X Genomics Inc (TXG)	61.5	8,018.1	616.9	-75.1	1.7	-9.3	--	10.2
Avantor (AVTR)	14.6	9,638.1	6,561.1	-578.0	-4.5	-10.3	--	1.7
Bio-Rad Laboratories	365.1	9,761.6	2,589.3	222.4	-6.0	3	44.5	1.3
Bruker (BRKR)	57.1	8,696.7	3,499.6	-71.2	0.5	-3.2	--	3.8
Glaukos Corp (GKOS)	179.9	10,905.5	612.8	-188.1	-30.6	-28.1	--	16.4
Lantheus Holdings (LNTH)	100.8	6,577.5	1,556.3	275.3	24.6	22.9	24.1	5.0
Penumbra (PEN)	321.7	12,752.7	1,504.9	160.6	13.6	10.9	79.4	8.4
Repligen (RGEN)	176.3	9,947.9	785.1	41.5	9.9	2	251.8	4.9
Smith & Nephew SNATS - ADR	29.0	12,153.4	6,164.0	625.0	13.0	11.8	19.9	2.4

Shareholding Pattern

View Details

About Neuropace Inc (NPCE)

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant... focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. Read more

Chief Medical Officer

Dr. Martha J. Morrell
Chief Medical Officer

Dr. Martha J. Morrell
Headquarters

Mountain View, CA
Website

https://www.neuropace.com

FAQs for Neuropace Inc (NPCE)

What is the current share price of Neuropace Inc (NPCE) Today?

The share price of Neuropace Inc (NPCE) is $14.41 (NASDAQ) as of 28-Aug-2026 16:22 EDT. Neuropace Inc (NPCE) has given a return of 33.92% in the last 3 years.

What is the current PB & PE ratio of Neuropace Inc (NPCE)?

Since, TTM earnings of Neuropace Inc (NPCE) is negative, P/E ratio is not available.
The P/B ratio of Neuropace Inc (NPCE) is 40.84 times as on 28-Aug-2026, a 978 premium to its peers’ median range of 3.79 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-23.54	26.55
2024	-12.33	41.78
2023	-8.11	12.95
2022	-0.79	1.06
2021	-6.75	3.31

What is the 52 Week High and Low of Neuropace Inc (NPCE)?

The 52-week high and low of Neuropace Inc (NPCE) are Rs 19.60 and Rs 8.85 as of 31-Aug-2026.

What is the market cap of Neuropace Inc (NPCE)?

Neuropace Inc (NPCE) has a market capitalisation of $ 495 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Neuropace Inc (NPCE)?

Before investing in Neuropace Inc (NPCE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.